http://hdl.handle.net/2268/103 Chercher dans ce canal chercher http://orbi.ulg.ac.be/simple-search http://hdl.handle.net/2268/149108 Titre: Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease <br/> <br/>Auteur, co-auteur: Hannon, Muriel; LECHANTEUR, Chantal; Lucas, Sophie; Somja, Joan; Seidel, Laurence; Belle, Ludovic; Bruck, France; BAUDOUX, Etienne; GIET, Olivier; Chantillon, André-Marie; Delvenne, Philippe; Drion, Pierre; Beguin, Yves; Humblet-Baron, Stéphanie; Baron, Frédéric http://hdl.handle.net/2268/149105 Titre: Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation <br/> <br/>Auteur, co-auteur: SERVAIS, Sophie; Beguin, Yves; Baron, Frédéric <br/> <br/>Résumé: Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment of choice for many patients suffering from hematological malignancies, severe hemoglobinopathies, bone marrow failures or severe primary immunodeficiencies. Graft rejection/failure (GF) is a life-threatening complication following allo-HSCT that is most commonly caused by the reactivity of recipient T cells, natural killer (NK) cells or antibodies against donor grafted hematopoietic cells. The increasing use of allo-HSCT following reduced-intensity conditioning (RIC) and the increasing use of alternative donors (unrelated cord blood and human leukocyte antigen (HLA)-mismatched donor) have resulted in higher frequency of GF. Areas covered: This review describes the pathogenesis and current prevention and treatment of GF as well as agents in development for GF prevention or treatment. Expert opinion: The risk of GF may be reduced in the future by optimizing the conditioning regimens and post-grafting immunosuppression, increasing the number of hematopoietic stem cells (HSCs) and/or immune cells transplanted, optimizing HSC homing and better detecting patients at high risk of GF by searching for pre-transplant donor-specific anti-HLA antibodies in patients given grafts from HLA-mismatched donors, or by closely monitoring donor T- and/or NK-cell chimerism after allo-HSCT following RIC. http://hdl.handle.net/2268/148955 Titre: Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. <br/> <br/>Auteur, co-auteur: JASPERS, Aurélie; Baron, Frédéric; WILLEMS, Evelyne; HAFRAOUI, Kaoutar; Vanstraelen, Gaëtan; Bonnet, Christophe; Beguin, Yves <br/> <br/>Résumé: Based on the impairment of erythropoietin production after allogeneic hematopoietic cell transplantation (HCT), we previously reported in a phase-2 trial that recombinant human erythropoietin (rhEPO) therapy was very efficient when started one month after transplantation. We also demonstrated that anemia after nonmyeloabalative (NM) HCT was less sensitive to rhEPO therapy than after conventional allogeneic HCT. This prompted us to confirm these findings in a prospective randomised trial. One hundred and thirty-one patients were randomised (1:1) between no treatment (arm 1) or erythropoietin (Neorecormon) at the dose of 500 U/kg/week (arm 2). Once the target Hb (13g/dL) has been attained, the dose of rhEPO was reduced by half, while it was withheld when Hb was = 14g/dL. Cohort A included 42 patients on day 28 after myeloablative HCT, cohort B 39 patients on day 28 after NMHCT, and cohort C 50 patients on day 0 of NMHCT. Primary endpoints included proportion of complete correctors (i.e. patients reaching Hb = 13g/dL) and median time to achieve Hb correction in each arm. The proportion of complete correctors before day 126 posttransplant was 0% in group 1A vs 52.4% in group 2A, 0% in group 1B vs 69.5% in group 2B and 19.1% in group 1C vs 70.2% in group 2C. Median time to achieve Hb = 13g/dL was not reached in group 1B vs 49 days in group 2B; 363 and 59 days in groups 1A and 1B respectively and 363 and 87 days in groups 3A and 3B respectively (figure 1). Hb evolution in each group is shown in figure 2. Seventyone patients (47/62 in control groups and 24/57 in treated groups, p=0.0003) required red blood cell transfusions. The difference was most pronounced in cohort B. There was no difference in rates of thrombo-embolic events or other complications between the two arms. In conclusion, this is the first trial to demonstrate that EPO therapy hastens erythroid recovery and decreases transfusion requirements when started one month after allogeneic HCT. http://hdl.handle.net/2268/148907 Titre: Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation <br/> <br/>Auteur, co-auteur: Binsfeld, Marilène; Belle, Ludovic; Hannon, Muriel; Hofgaard; Dubois, Sophie; Otjacques, Eléonore; BEGUIN, Yves; Bogen; BARON, Frédéric; CAERS, Jo http://hdl.handle.net/2268/148906 Titre: Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells <br/> <br/>Auteur, co-auteur: Bruck, France; Baron, Frédéric; DUBOIS, Sophie; BRIQUET, Alexandra; Hannon, Muriel; Belle, Ludovic; MENTEN, Catherine; Beguin, Yves; Humblet-Baron, S. http://hdl.handle.net/2268/148905 Titre: Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells <br/> <br/>Auteur, co-auteur: Bruck, France; BARON, Frédéric; Dubois, Sophie; BRIQUET, Alexandra; Hannon, Muriel; Belle, Ludovic; MENTEN, Catherine; BEGUIN, Yves; Humblet-Baron, Stéphanie http://hdl.handle.net/2268/148904 Titre: What Is The Role For Regulatory T-Cells After Nonmyeloablative Conditioning? <br/> <br/>Auteur, co-auteur: Humblet-Baron, S.; CASTERMANS, Emilie; Vanbellinghen, J.-F.; Hannon, Muriel; Jacobs, Nathalie; WILLEMS, Evelyne; Ormenese, Sandra; Beguin, Yves; Baron, Frédéric http://hdl.handle.net/2268/148903 Titre: Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft <br/> <br/>Auteur, co-auteur: SERVAIS, Sophie; Hannon, Muriel; Daulne, Coline; Gothot, André; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract I92 http://hdl.handle.net/2268/148901 Titre: What is the Role for Regulatory T-Cells after Nonmyeloablative conditioning <br/> <br/>Auteur, co-auteur: Humblet-Baron, S.; CASTERMANS, Emilie; Vanbellighen, J.-F.; Hannon, Muriel; Jacobs, Nathalie; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract 373 http://hdl.handle.net/2268/148900 Titre: Comparison of Immune Reconstitution after Non-myeloablative Hematopoietic Cell Transplantation (HCT) with Flu-TBI versus TLI-ATG Conditioning <br/> <br/>Auteur, co-auteur: Hannon, Muriel; Humblet-Baron, S.; Graux, C.; Maertens, J.; Kerre, T.; Daulne, C.; Willems, E.; Gothot, André; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract O.07 http://hdl.handle.net/2268/148898 Titre: Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease <br/> <br/>Auteur, co-auteur: Bruck, France; de Leval, Laurence; Belle, Ludovic; LECHANTEUR, Chantal; Hannon, Muriel; BRIQUET, Alexandra; Dubois, Sophie; CASTERMANS, Emilie; Humblet-Baron, Stéphanie; Rahmouni, Souad; BEGUIN, Yves; BARON, Frédéric http://hdl.handle.net/2268/148896 Titre: The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells <br/> <br/>Auteur, co-auteur: Bruck, France; BARON, Frédéric; Dubois, Sophie; BRIQUET, Alexandra; Hannon, Muriel; Belle, Ludovic; MENTEN, Catherine; BEGUIN, Yves; Humblet-Baron, Stéphanie http://hdl.handle.net/2268/148894 Titre: Imatinib and Nilotinib do not prevent adhesion and migration of human CD34+ in vitro and in immunodeficient mice <br/> <br/>Auteur, co-auteur: Belle, Ludovic; Bruck, France; FOGUENNE, Jacques; GOTHOT, André; BEGUIN, Yves; BARON, Frédéric; BRIQUET, Alexandra http://hdl.handle.net/2268/148890 Titre: Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age. <br/> <br/>Auteur, co-auteur: Castermans, Emilie; Hannon, Muriel; Cheynier, Remi; Seidel, Laurence; Humblet-Baron, Stephanie; WILLEMS, Evelyne; Corbier, S.; Gothot, André; Geenen, Vincent; Sandmaier, Brenda M.; Storb, Rainer F.; Beguin, Yves; Baron, Frédéric http://hdl.handle.net/2268/148884 Titre: Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft <br/> <br/>Auteur, co-auteur: SERVAIS, Sophie; Hannon, Muriel; Daulne, Coline; Gothot, André; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract P.73 http://hdl.handle.net/2268/148882 Titre: Evidence for Expansion of Host-derived CMV-specific CD8+ T cells after Allogeneic Transplantation with Non-Myeloablative Conditioning <br/> <br/>Auteur, co-auteur: MENTEN, Catherine; Castermans, E.; Hannon, Muriel; Ormenese, Sandra; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract P.06 http://hdl.handle.net/2268/148880 Titre: What is the Contribution of Host-Derived CMV Immunity after Allogeneic Transplantation following Non-Myeloablative Conditioning? <br/> <br/>Auteur, co-auteur: MENTEN, Catherine; Castermans, E.; Hannon, Muriel; Ormenese, Sandra; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract P.1868 http://hdl.handle.net/2268/148877 Titre: Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice <br/> <br/>Auteur, co-auteur: Belle, Ludovic; Baron, Frédéric; Bruck, France; Hannon, Muriel; SERVAIS, S.; Beguin, Yves; BRIQUET, Alexandra <br/> <br/>Commentaires: Abstract P.76 http://hdl.handle.net/2268/148876 Titre: Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning <br/> <br/>Auteur, co-auteur: Hannon, Muriel; Humblet-Baron, S.; Graux, C.; Maertens, J.; Kerre, T.; Theunissen, K.; Daulne, C.; Willems, E.; Belle, Ludovic; Binsfeld, Marilène; Gothot, André; Beguin, Yves; Baron, Frédéric <br/> <br/>Commentaires: Abstract P.0448 http://hdl.handle.net/2268/148875 Titre: Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation <br/> <br/>Auteur, co-auteur: Binsfeld, Marilène; Belle, Ludovic; Hannon, Muriel; DUBOIS, Sophie; Otjacques, Eléonore; Beguin, Yves; Baron, Frédéric; CAERS, Jo <br/> <br/>Commentaires: Abstract P.07